What the FDA labels say about taking them together
Ergotamine and mifepristone
Mifepristone's FDA label of September 25, 2025 names ergotamine in its contraindications section; the ergotamine label PlainMeds reads does not name mifepristone. The mifepristone label: “… CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, due to an increased risk of adverse events. …”
Check it at the source: the ergotamine FDA label on DailyMed (effective February 25, 2025, Pangea Pharmaceuticals LLC); the mifepristone FDA label on DailyMed (effective September 25, 2025, Corcept Therapeutics Incorporated).
What does the ergotamine label say about mifepristone?
Ergotamine's label (effective February 25, 2025) does not name mifepristone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Ergomar Sublingual), Pangea Pharmaceuticals LLC, effective February 25, 2025 (SPL set a9582fdb-7ddd-4f69-aa7a-66247cdb8c92), via openFDA; the full label on DailyMed
What does the mifepristone label say about ergotamine?
Mifepristone label, contraindicationsCONTRAINDICATIONS Mifepristone is contraindicated in: Pregnancy [See Dosage and Administration ( 2.1 ), Use in Specific Populations ( 8.1 , 8.3 )] Patients taking drugs metabolized by CYP3A such as simvastatin, lovastatin, and CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, due to an increased risk of adverse events. [See Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] Patients receiving systemic corticosteroids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because mifepristone antagonizes the effect of glucocorticoids.
Mifepristone label, drug interactionsConcomitant use of simvastatin or lovastatin is contraindicated because of the increased risk of myopathy and rhabdomyolysis. [See Contraindications (4.2), Clinical Pharmacology 12.3 ] The exposure of other substrates of CYP3A with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, may be increased by concomitant administration with mifepristone.
Source: FDA drug label (Mifepristone), Corcept Therapeutics Incorporated, effective September 25, 2025 (SPL set 63c068cd-9370-460f-829b-70e8c7ebe91e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ergotamine | Mifepristone | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $43.46 per tablet 2 mg tablet sublingual | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once